Work

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies

Year: 2012

Type: article

Abstract: Rapamycin/Sirolimus™ leads to the regression of transplant- associated Kaposi sarcoma (KS). It also leads to disease stabilization in HIV-associated KS. Case reports and a wealth of preclinical studies support rapamycin’s efficacy also in AIDS associated lymphoma, such as primary effusion lymphoma (PEL). Rapamycin inhibits the mammalian target of rapamycin (mTOR) and papamycin derivatives are approved for the treatment of mantle cell lymphoma and other cancers. It is not universally effective against all solid tumors. Even within this group of clinically responsive cancers, there are exceptions of cases or cell models in which this drug or its derivatives (rapalogs) fail.

Source: Infectious Agents and Cancer

DOI: 10.1186/1750-9378-7-s1-o9

Authors: Dirk P Dittmer, Blossom Damania, Sang-Hoon Sin, Debasmita Roy

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,190